公开(公告)号：US20240350476A1

公开(公告)日：2024-10-24

申请号：US18620823

申请日：2024-03-28

Applicant: LUCY GOODS, INC.

Inventor： Ryan Tanakit ,  Samy Hamdouche ,  David Renteln ,  Tod Miller

IPC: A61K31/465 ,  A61K9/00 ,  A61K9/70 ,  A61P25/34

CPC classification number: A61K31/465 ,  A61K9/006 ,  A61K9/7015 ,  A61P25/34

Abstract: Disclosed herein are smoking cessation products comprising 6-methylnicotine and methods of treating nicotine addiction using a smoking cessation production comprising 6-methylnicotine.

公开(公告)号：US20230338339A1

公开(公告)日：2023-10-26

申请号：US18216890

申请日：2023-06-30

Applicant: BioXcel Therapeutics, Inc.

Inventor： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC: A61K31/4174 ,  A61P25/18 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

CPC classification number: A61K31/4174 ,  A61P25/18 ,  A61K9/006 ,  A61K9/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/7007 ,  A61K9/7015 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US11766469B2

公开(公告)日：2023-09-26

申请号：US17086786

申请日：2020-11-02

Applicant: Quthero, Inc.

Inventor： Serena Mandla ,  Milica Radisic

IPC: A61K38/08 ,  A61K38/16 ,  A61K38/00 ,  A61P17/02 ,  A61F13/00 ,  A61K9/70 ,  A61K9/14 ,  A61K38/18 ,  C12N5/077 ,  A61K47/61 ,  A61K9/06 ,  G01N33/68 ,  A61K47/42

CPC classification number: A61K38/1891 ,  A61K9/06 ,  A61K9/14 ,  A61K9/70 ,  A61K9/7007 ,  A61K9/7015 ,  A61K38/08 ,  A61K47/42 ,  A61K47/61 ,  A61P17/02 ,  C12N5/0669 ,  G01N33/6893 ,  C12N2501/17

Abstract: The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.

公开(公告)号：US11648212B2

公开(公告)日：2023-05-16

申请号：US16053383

申请日：2018-08-02

Applicant: Intelgenx Corp.

Inventor： Mobarik Bilal ,  Rodolphe Obeid ,  Nadine Paiement

IPC: A61K31/553 ,  A61K47/10 ,  A61K47/28 ,  A61K9/70 ,  A61K9/00 ,  A61K47/36 ,  A61K47/32 ,  A61K47/26 ,  A61K47/18 ,  A61K47/38

CPC classification number: A61K9/7015 ,  A61K9/006 ,  A61K9/7007 ,  A61K31/553 ,  A61K47/10 ,  A61K47/186 ,  A61K47/26 ,  A61K47/28 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.

公开(公告)号：US20180338986A1

公开(公告)日：2018-11-29

申请号：US16054353

申请日：2018-08-03

Applicant: Dr. Reddy's Laboratories Ltd.

Inventor： Udhumansha UBAIDULLA ,  Sateesh KANDAVILLI ,  Ajay Sunil VAIRALE ,  Jeffrey A. WAYNE ,  Vijendra NALAMOTHU ,  Mistry MEGHAL ,  Refika Isil PAKUNLU

IPC: A61K31/573 ,  A61K47/22 ,  B05B15/30 ,  A61K47/26 ,  A61K47/44 ,  A61K47/38 ,  A61K47/36 ,  A61K47/32 ,  A61K47/14 ,  A61K47/10 ,  A61K31/58 ,  A61K31/575 ,  A61K31/56 ,  A61K9/70 ,  A61K9/00 ,  B05B11/00 ,  B05B1/02 ,  B05B1/30 ,  A61K9/107

CPC classification number: A61K31/573 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/7015 ,  A61K31/56 ,  A61K31/575 ,  A61K31/58 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  B05B1/02 ,  B05B1/30 ,  B05B11/3045 ,  B05B15/30

Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

公开(公告)号：US20180271777A1

公开(公告)日：2018-09-27

申请号：US15928962

申请日：2018-03-22

Applicant: AGIGMA Inc.

Inventor： Nevenka Golubovic-Liakopoulos ,  Bhavdeep Shah ,  Erik Andersen

IPC: A61K9/00 ,  A61K8/02 ,  A61K8/03 ,  A61K8/65 ,  A61K8/66 ,  A61K8/73 ,  A61K9/70 ,  A61K31/19 ,  A61K31/196 ,  A61K31/728 ,  A61Q19/00

CPC classification number: A61K9/0014 ,  A61K8/0208 ,  A61K8/027 ,  A61K8/03 ,  A61K8/65 ,  A61K8/66 ,  A61K8/731 ,  A61K8/733 ,  A61K9/70 ,  A61K9/7007 ,  A61K9/7015 ,  A61K31/19 ,  A61K31/196 ,  A61K31/728 ,  A61K2800/88 ,  A61K2800/884 ,  A61Q19/00

Abstract: The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

公开(公告)号：US10080763B2

公开(公告)日：2018-09-25

申请号：US14828184

申请日：2015-08-17

Applicant: Sidmak Laboratories (India) Pvt. Ltd.

Inventor： Vinayak T. Bhalani ,  Anjan Kumar Paul ,  Ashim Kumar Sarkar

IPC: A61K9/70 ,  A61K31/65 ,  A61K9/00 ,  A61K31/167 ,  A61K31/196 ,  A61K31/202 ,  A61K31/203 ,  A61K31/465 ,  A61K31/496 ,  A61K9/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/32 ,  A61K47/36

CPC classification number: A61K31/65 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7015 ,  A61K31/167 ,  A61K31/196 ,  A61K31/202 ,  A61K31/203 ,  A61K31/465 ,  A61K31/496 ,  A61K47/10 ,  A61K47/14 ,  A61K47/32 ,  A61K47/36

Abstract: The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release. The formed film is characterized by: locally sustained levels of a minimum effective concentration (MEC) of the active agent between applications; its adherence and conformance to a surface of the skin; its pliability, its resistance to breaking under tension (tensile strength); maintained potency of the active agent; and removability of the film from the skin without a residue.

公开(公告)号：US20180117167A1

公开(公告)日：2018-05-03

申请号：US15568266

申请日：2016-04-20

Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.

Inventor： Hyeon-A YIM ,  Hee-Chul CHANG

IPC: A61K47/59 ,  A61K9/70 ,  A61K31/192 ,  A61K31/165 ,  A61L26/00

CPC classification number: A61K47/59 ,  A61K9/7015 ,  A61K9/7069 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61L26/0019 ,  A61L26/0066 ,  A61L26/0085 ,  A61L2300/41 ,  C08L75/04

Abstract: Provided is a process for preparing a polyurethane foam dressing in which an anti-inflammatory agent is homogeneously dispersed, the process including obtaining a drug (i.e., anti-inflammatory agent)-containing polyurethane prepolymer using a certain dispersing agent; and reacting the drug-containing polyurethane prepolymer with a water-containing blowing solution to form a polyurethane foam and then drying the polyurethane foam.

公开(公告)号：US09931305B2

公开(公告)日：2018-04-03

申请号：US15438458

申请日：2017-02-21

Applicant: MonoSol Rx, LLC

Inventor： Robert K. Yang ,  Richard C. Fuisz ,  Garry L. Myers ,  Joseph M. Fuisz

IPC: A61K9/70 ,  A61K47/34 ,  A61K47/32 ,  A61K31/567 ,  A61K31/138 ,  A61K31/635 ,  A61K31/44 ,  A61K31/7048 ,  A61K31/4545 ,  A61K31/192 ,  A61K9/00 ,  A61K47/38

CPC classification number: A61K9/7007 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5047 ,  A61K9/7015 ,  A61K31/138 ,  A61K31/192 ,  A61K31/422 ,  A61K31/44 ,  A61K31/4422 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/549 ,  A61K31/567 ,  A61K31/635 ,  A61K31/704 ,  A61K31/7048 ,  A61K47/02 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  A61K47/46 ,  B05D3/0254 ,  B29C47/0004

Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

公开(公告)号：US20180042764A1

公开(公告)日：2018-02-15

申请号：US15674182

申请日：2017-08-10

Applicant: Ferndale Laboratories, Inc.

Inventor： Israel Dvoretzky ,  Michael Burns

IPC: A61F7/03 ,  A61K31/4745 ,  A61K9/70 ,  A61K9/00 ,  A61K47/02 ,  A61K31/122 ,  A61K41/00

CPC classification number: A61F7/034 ,  A61F2007/0052 ,  A61F2007/0226 ,  A61F2007/0261 ,  A61F2007/0263 ,  A61F2007/036 ,  A61K9/0014 ,  A61K9/7007 ,  A61K9/7015 ,  A61K31/122 ,  A61K31/4745 ,  A61K41/0052 ,  A61K47/02

Abstract: Methods of treating a wart are provided which include: providing a heating device having a central zone and peripheral zone, sized to cover the wart and skin peripheral to the wart, and including a heat-generating material that undergoes an exothermic reaction when exposed to oxygen; providing a liquid therapeutic adhesive comprising a volatile solvent, skin-compatible adhesive and therapeutic agent; applying the liquid therapeutic adhesive to the skin peripheral to the wart or to the peripheral zone of the heating device; initiating the exothermic reaction of the heat-generating material by exposure of the heat-generating material to oxygen; applying the central zone of the heating device to contact the wart, thereby heating the wart and skin peripheral to the wart to an elevated skin temperature; and maintaining the elevated skin temperature for a period of time, thereby creating an enclosed heated environment treating the wart and skin peripheral to the wart.